51 patents
Utility
Pharmaceutical Formulations for Treating Diseases Associated with Voltage-gated Sodium Channels
21 Dec 23
Jean-Jacques Alexandre Cadieux, Matthew David Tandy
Filed: 9 Apr 21
Utility
Use of the NAV1.6 Sodium Channel Blocker (S)-4-((1-BENZYLPYRROLIDIN-3-YL)(METHYL)AMINO)-2-FLUORO-5-METHYL-N(THIAZOL-4-YL)BENZENESULFONAMIDE, Together with Strong Inducers of Cytochrome P450 3A4, In the Treatment of Conditions Associated with NAVI.6 Activity
21 Dec 23
Provided are methods for treating diseases or conditions associated with Nav1.6 activity in a patient, comprising administering to said patient (S)-4((1-benzylpyrrolidin-3-yl)(methypamino)-2-fluoro-5-methyl-N(thiazol-4-yl)benzenesulfonamide or a pharmaceutically acceptable salt thereof, wherein the patient is also being administered a strong inducer of cytochrome P450 3A4 (CYP3A4).
Gregory N. Beatch, Rostam Namdari
Filed: 9 Apr 21
Utility
Pyridinylacetamide Derivatives As Sodium Channel Activators
29 Jun 23
Verner Alexander Lofstrand, Jung Yun Kim, Helen Clement, Kristen Nicole Burford, Paul Charifson, Shawn Johnstone, Juliette Sabbatani, Jan Felix Scholtes, Wei Zhang, Shaoyi Sun, Michael Clark, Steve Wesolowski, Ravi Munuganti, Ramkumar Rajamani
Filed: 23 Sep 22
Utility
Pyridinyl Derivatives As Sodium Channel Activators
18 May 23
Verner Alexander Lofstrand, Jung Yun Kim, Helen Clement, Kristen Nicole Burford, Paul Charifson, Michael Clark
Filed: 23 Sep 22
Utility
Pyridine Derivatives and Their Use As Sodium Channel Activators
11 May 23
Verner Alexander Lofstrand, Jung Yun Kim, Helen Clement, Kristen Nicole Burford, Paul Charifson, Shawn Johnstone, Juliette Sabbatani, Jan Felix Scholtes, Wei Zhang, Shaoyi Sun
Filed: 23 Sep 22
Utility
Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents
2 May 23
This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.
Jean-Christophe Andrez, Kristen Nicole Burford, Christoph Martin Dehnhardt, Thilo Focken, Michael Edward Grimwood, Qi Jia, Verner Alexander Lofstrand, Shaoyi Sun, Steven Sigmund Wesolowski, Michael Scott Wilson, Alla Yurevna Zenova
Filed: 24 Feb 21
Utility
Heteroaryl-substituted Sulfonamide Compounds and Their Use As Therapeutic Agents
3 Nov 22
This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.
Jean-Christophe Andrez, Kristen Nicole Burford, Christoph Martin Dehnhardt, Thilo Focken, Michael Edward Grimwood, Qi Jia, Verner Alexander Lofstrand, Shaoyi Sun, Steven Sigmund Wesolowski, Michael Scott Wilson, Alla Yurevna Zenova
Filed: 24 Feb 21
Utility
Conjoint Therapy for Treating Seizure Disorders
15 Sep 22
In certain embodiments, the present disclosure is directed to methods and uses for treating seizure disorders in a human in need thereof, wherein the methods and uses comprise conjointly administering N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A) and an antiseizure medication (ASM) to the human in amounts that are therapeutically effective when conjointly administered.
James Philip JOHNSON, JR.
Filed: 9 Feb 22
Utility
Methods and Uses for Treating Anhedonia
25 Aug 22
The present disclosure is directed to, among other things, methods and uses for treating anhedonia in a subject, such as a human, wherein the methods comprise administering a therapeutically effective amount of N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A) to the subject in need thereof, and the uses comprise Compound A for use in treating anhedonia in a subject, such as a human.
Simon Neil PIMSTONE
Filed: 9 Feb 22
Utility
Methods for Treating Absence Seizures
23 Jun 22
In certain embodiments, the present disclosure is directed to methods and uses of flunarizine, including for treating absence seizures in a human patient, such as absence seizures in childhood absence epilepsy (CAE), wherein the methods comprise administering (e.g., orally) to a patient in need thereof a therapeutically effective amount of flunarizine.
Robin Paul SHERRINGTON, Mary B. CONNOLLY
Filed: 22 Nov 21
Utility
Benzenesulfonamide compounds and their use as therapeutic agents
10 May 22
This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.
Kristen Nicole Burford, Thilo Focken, Verner Alexander Lofstrand, Michael Scott Wilson, Alla Yurevna Zenova
Filed: 13 Jul 20
Utility
Methods for Enhancing the Bioavailability and Exposure of a Voltage-gated Potassium Channel Opener
3 Mar 22
In certain embodiments, the present disclosure is directed to methods and uses for treating seizure disorders in a human, wherein the methods and uses comprise orally administering a therapeutically effective amount of the voltage-gated potassium channel allosteric modulator, N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A), to the human in need thereof, for example, under fed conditions.
Gregory N. BEATCH
Filed: 1 Oct 21
Utility
Solid State Forms of a Selective Potassium Channel Modulator
3 Mar 22
The present disclosure provides solid state forms of a selective potassium channel modulator and pharmaceutical compositions comprising the solid state crystalline forms and pharmaceutically acceptable excipients, and methods for preparing and using the solid state forms and the pharmaceutical compositions thereof.
Paul Robert BICHLER, Jean-Jacques Alexandre CADIEUX, Matthew David TANDY, Gregory N. BEATCH
Filed: 6 Jul 21
Utility
Therapeutic Compounds and Methods of Use Thereof
24 Feb 22
Ivan William HEMEON, Brian SAFINA, Daniel SUTHERLIN
Filed: 6 Aug 21
Utility
Substituted benzamides and methods of use thereof
21 Dec 21
Sultan Chowdhury, Christoph Martin Dehnhardt, Thilo Focken, Michael Edward Grimwood, Ivan William Hemeon, Steven McKerrall, Daniel Sutherlin
Filed: 3 Sep 20
Utility
Benzenesulfonamide compouds and their use as therapeutic agents
16 Nov 21
This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.
Jean-Christophe Andrez, David Earl Bogucki, Kristen Nicole Burford, Sultan Chowdhury, Charles Jay Cohen, Shannon Marie Decker, Christoph Martin Dehnhardt, Robert Joseph Devita, James Roy Empfield, Thilo Focken, Michael Edward Grimwood, Syed Abid Hasan, Qi Jia, James Philip Johnson, Jr., Michael Scott Wilson, Alla Yurevna Zenova
Filed: 2 Mar 20
Utility
Therapeutic compounds and methods of use thereof
19 Oct 21
Jean-Christophe Andrez, Philippe Bergeron, Paul Robert Bichler, Sultan Chowdhury, Christoph Martin Dehnhardt, Thilo Focken, Wei Gong, Michael Edward Grimwood, Abid Hasan, Ivan William Hemeon, Qi Jia, Brian Salvatore Safina, Shaoyi Sun, Michael Scott Wilson, Alla Yurevna Zenova
Filed: 3 Dec 19
Utility
Methods for enhancing the bio availability and exposure of a voltage-gated potassium channel opener
5 Oct 21
In certain embodiments, the present disclosure is directed to methods and uses for treating seizure disorders in a human, wherein the methods and uses comprise orally administering a therapeutically effective amount of the voltage-gated potassium channel allosteric modulator, N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A), to the human in need thereof, for example, under fed conditions.
Gregory N. Beatch
Filed: 13 May 19
Utility
Therapeutic compounds and methods of use thereof
28 Sep 21
Ivan William Hemeon, Brian Salvatore Safina, Daniel Sutherlin
Filed: 15 Nov 19
Utility
Substituted Benzamides and Methods of Use Thereof
19 Aug 21
Chien-an CHEN, Sultan CHOWDHURY, Shannon Marie DECKER, Christoph Martin DEHNHARDT, Ivan William HEMEON, Steven MCKERRALL, Brian SAFINA, Tao SHENG, Dan SUTHERLIN
Filed: 19 Jan 21